USA – Verve Therapeutics, a Cambridge, Mass.-based biotech company pioneering gene editing medicines to treat cardiovascular disease, closed a $94m Series B financing.
The round was led by Wellington Management Company and co-led by Casdin Capital with participation from Redmile Group, Janus Henderson Investors, Cormorant Asset Management, Rock Springs Capital, Novo Holdings A/S, Logos Capital, Surveyor Capital (a Citadel company), RA Capital Management, GV and Biomatics.The company intends to use the funds to advance its pipeline of gene editing medicines, led by VERVE-101, and further extend its scientific and technical leadership. Led by Sekar Kathiresan, M.D., chief executive officer, Verve isis a biotechnology company developing VERVE-101, comprised of a messenger RNA for adenine base editing and a guide RNA for PCSK9 gene targeting, packaged in a lipid nanoparticle delivery vehicle, for the initial treatment of heterozygous familial hypercholesterolemia (HeFH), a potentially fatal genetic heart disease.19/01/2020
